Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Q3 2012 Earnings Call
October 23, 2012 5:15 pm ET
Arvind Sood - Vice President of Investor Relations
Robert A. Bradway - Chief Executive Officer, President, Chief Operating Officer and Director
Jonathan M. Peacock - Chief Financial Officer and Executive Vice President
Anthony C. Hooper - Executive Vice President of Global Commercial Operations
Sean E. Harper - Executive Vice President of Research & Development
Michael J. Yee - RBC Capital Markets, LLC, Research Division
Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division
Eric Schmidt - Cowen and Company, LLC, Research Division
Geoffrey C. Meacham - JP Morgan Chase & Co, Research Division
Robyn Karnauskas - Deutsche Bank AG, Research Division
Marshall Urist - Morgan Stanley, Research Division
M. Ian Somaiya - Piper Jaffray Companies, Research Division
Rachel L. McMinn - BofA Merrill Lynch, Research Division
Christopher J. Raymond - Robert W. Baird & Co. Incorporated, Research Division
Boris Peaker - Oppenheimer & Co. Inc., Research Division
Yaron Werber - Citigroup Inc, Research Division
Eun K. Yang - Jefferies & Company, Inc., Research Division
Mark J. Schoenebaum - ISI Group Inc., Research Division
Joshua Schimmer - Lazard Capital Markets LLC, Research Division
Jim Birchenough - BMO Capital Markets U.S.
Lee Kalowski - Crédit Suisse AG, Research Division
Howard Liang - Leerink Swann LLC, Research Division
Charles Anthony Butler - Barclays Capital, Research Division
Joel D. Sendek - Stifel, Nicolaus & Co., Inc., Research Division
Previous Statements by AMGN
» Amgen Management Discusses Q2 2012 Results - Earnings Call Transcript
» Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» Amgen's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thank you, Marvin. Good afternoon, everybody. I would like to welcome you to our Third Quarter Conference Call. We once again delivered solid revenue and earnings per share growth, which is a good indicator of our business momentum.
To discuss this and other topics, including recent and upcoming data presentations and scientific forums for some of our key pipeline products, I'm joined today by several members of our leadership team. Our CEO, Bob Bradway, will lead the call today, with providing a strategic overview. After Bob, our CFO, Jon Peacock, will review our quarterly results and update our guidance for the year. Our Head of Global Commercial Operations, Tony Hooper, will highlight our product performance, followed by our Head of R&D, Sean Harper, who will provide a pipeline update. After Sean's presentation, we'll have plenty of time for questions.
We will use slides for our presentation today. These slides have been posted on our website, and a link was sent to you separately by email. Our comments today will be governed by our Safe Harbor statement, which, in summary, says that through the course of our presentation today, we may make certain forward-looking statements, and actual results may vary materially.
So with that, I would like to turn the call over to Bob. Bob?
Robert A. Bradway
Okay. Thank you, Arvind. Good afternoon, everyone, and thank you for joining our call. You can see from our results through the first 3 quarters of the year, our business has very good momentum, and we're executing on our strategy to grow the business and deliver for patients and shareholders.
We'll talk more about strategy in our business review in February, but for now, I'd like to point out that even as we're investing heavily to develop several breakthrough therapies for the future, our currently commercialized products are providing attractive shareholder returns and opportunities for growth.
The momentum we have with these products has given us confidence to increase our revenue and EPS guidance for the year, and we'll provide more detail on that shortly.
In terms of our third quarter results, we again posted solid revenue and earnings growth through strong commercial execution and a focus on expense discipline. On the commercial front, we're particularly pleased with the continued strength of our Enbrel franchise, and Tony will have more to say about that in a moment.
And we're excited as well about the many emerging opportunities from our pipeline, notably AMG 785 and AMG 145. The recent presentation of the Phase II osteoporosis data for AMG 785, now known as romosozumab, generated a lot of excitement at ASBMR. Similarly, we're looking forward to the presentation of Phase II data from AMG 145, our PCSK9 antibody in development for hypercholesterolemia, at the American Heart Association meeting in a couple of weeks. And Sean will have an opportunity in a few moment's time to detail recent developments from our pipeline.
Before I turn it over to John to discuss our financials, I'd like to just take a moment to thank all of our staff for their dedication and hard work. It's through their efforts and dedication that we're able to deliver both important new therapies for patients and value for our shareholders.
So with that, let me turn to John for the financial review.
Jonathan M. Peacock
Thanks, Bob. So as you can see from the slides, this was a strong quarter for us on revenues, on earnings and on cash flows.
First of all, on revenues on Page 4, we were 10% higher, reflecting the continued strength across the portfolio. The key drivers were Enbrel, Prolia, XGEVA and our growth phase products, Sensipar, Vectibix and Nplate said. Tony will give you more color on our product sales in a few moments.
Other revenues included a milestone payment received on the initiation of the Phase III psoriasis study for brodalumab, the -- and the growth in Other Revenues overall in 2012 reflects our continued focus on portfolio decisions between the molecules that we choose to wholly own and those we believe will deliver greater value through partnering or outlicensing. But overall, 10% growth in revenues for the quarter.